Lifecore Biomedical, Inc. De 8-K, filed Oct 19, 2020
Lifecore Biomedical, Inc. De (LFCR)
8-K
2020-10-19
For: 2020-10-14
View Original
Added on
April 12, 2026
About this 8-K
Lifecore Biomedical, Inc. De filed this 8-K on October 19, 2020, reporting on events of October 14, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 5.03: Charter or bylaw amendment, or fiscal year change
- Item 5.07: Shareholder vote results
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 14, 2020
LANDEC CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 000-27446 | 94-3025618 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (State or other jurisdiction of incorporation) | (Commission file number) | (IRS Employer Identification No.) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2811 Airpark Drive Santa Maria, California | 93455 | |||||||||||||||||||||||||||||||||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||||||||||||||||||||||||||||||||
(650) 306-1650
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
| Common Stock, par value $.001 per share | LNDC | The NASDAQ Global Select Market | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) As previously disclosed, effective as of the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”), held on October 14, 2020, Fredrick Frank retired from the Board of Directors (the “Board”) of Landec Corporation (the “Company”). Mr. Frank’s retirement was not due to any disagreement with the Company.
(e) On October 14, 2020, the Board approved the performance criteria and structure for cash bonuses that may be awarded to employees of the Company and its subsidiaries Curation Foods, Inc. (“Curation Foods”) and Lifecore Biomedical, Inc. (“Lifecore”), including the Company’s named executive officers, for the 2021 fiscal year.
Bonuses will be determined based on actual achievement of applicable EBITDA goals, and will range from 0% - 150% (for the Company or Curation employees) or 200% (for Lifecore employees) of the employee’s target bonus. For employees of the Company, Curation Foods and Lifecore, bonuses will be based on the achievement of adjusted EBITDA goals for the 2021 fiscal year established for the Company, Curation Foods and Lifecore, respectively. No bonus will be payable to employees of the Company or Curation Foods if the adjusted EBITDA actually achieved is equal to or less than 87.5% of the applicable adjusted EBITDA target; for Lifecore employees, no bonus will be payable if the adjusted EBITDA actually achieved is equal to or less than 93.3% of the applicable adjusted EBITDA target. To receive any bonus, a participant must be employed at the end of the 2021 fiscal year.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On October 14, 2020, following approval by the stockholders of the Company at the Annual Meeting, the Company executed Amendment No. 3 (the “Bylaws Amendment”) to the Company’s Amended and Restated By-laws, which increased the maximum size of the Board to 12 directors.
The foregoing description of the Bylaws Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws Amendment, which is filed as Exhibit 3.1 hereto and incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On October 14, 2020, the Company held the Annual Meeting. As of the close of business on August 17, 2020, the record date for the Annual Meeting, there were 29,241,889 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. The four proposals presented to the stockholders of the Company at the Annual Meeting were (1) the election of six directors for a two year term and one director, Joshua E. Schechter, for a one year term, (2) the approval of the Bylaws Amendment, (3) the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2021, and (4) the approval of a non-binding advisory proposal on the executive compensation of the Company’s named executive officers.
1.The voting results for the election of directors were as follows:
| Director | Votes For | Votes Withheld | Broker Non-Votes | ||||||||
| Katrina L. Houde | 24,263,238 | 438,890 | 1,411,002 | ||||||||
| Nelson Obus | 23,541,134 | 1,160,994 | 1,411,002 | ||||||||
| Andrew Powell | 23,776,978 | 925,150 | 1,411,002 | ||||||||
| Catherine A. Sohn | 23,757,628 | 944,500 | 1,411,002 | ||||||||
| Jeffrey Edwards | 23,897,666 | 804,462 | 1,411,002 | ||||||||
| Patrick Walsh | 24,179,901 | 522,227 | 1,411,002 | ||||||||
| Joshua E. Schechter | 21,335,077 | 3,367,051 | 1,411,002 | ||||||||
As a result of the foregoing voting results, and the approval of the Bylaws Amendment, each of the foregoing directors was appointed to our Board, to serve until the expiration of their respective terms and until their successors are duly elected and qualified.
2.The Bylaws Amendment was approved, with votes as follows:
| For | Against | Abstain | Broker Non-Votes | ||||||||
| 24,073,243 | 618,114 | 10,771 | 1,411,002 | ||||||||
3.Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2021, with votes as follows:
| For | Against | Abstain | |||||||||
| 25,984,435 | 120,961 | 7,734 | |||||||||
4.Stockholders approved the compensation paid to the Company’s named executive officers (in the form of a non-binding, advisory vote), with votes as follows:
| For | Against | Abstain | Broker Non-Votes | ||||||||
| 23,788,131 | 349,277 | 564,720 | 1,411,002 | ||||||||
Item 8.01 Other Events.
On October 14, 2020, following the Annual Meeting, Craig A. Barbarosh was appointed as Chairman of the Board. In addition, on October 14, 2020, the Board made the following committee appointments:
•Tonia Pankopf, Charles Macaluso, Katrina L. Houde and Catherine A. Sohn were appointed to the Board’s Audit Committee, with Ms. Pankopf to serve as chair of the Audit Committee;
•Deborah Carosella, Andrew Powell, Nelson Obus and Jeffrey Edwards were appointed to the Board’s Compensation Committee, with Ms. Carosella to serve as chair of the Compensation Committee;
•Mr. Powell, Mr. Obus, Mr. Schechter, Ms. Pankopf and Patrick Walsh were appointed to the Board’s Nominating and Corporate Governance Committee, with Mr. Powell to serve as chair of the Nominating and Corporate Governance Committee;
•Ms. Houde, Ms. Carosella, Mr. Macaluso, Mr. Schechter and Mr. Obus were appointed to the Board’s Curation Focus Committee, with Ms. Houde to serve as chair of the Curation Focus Committee and Albert D. Bolles and Mr. Barbarosh to serve as “ex officio” members; and
•Mr. Walsh, Mr. Edwards, Ms. Sohn, Mr. Powell and Ms. Pankopf were appointed to the Board’s Lifecore Focus Committee, with Mr. Walsh to serve as chair of the Lifecore Focus Committee and James Hall and Mr. Barbarosh to serve as “ex officio” members.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibit.
The following exhibits are furnished as part of this report:
| Exhibit No. | Description | |||||||
| 3.1 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 19, 2020
| LANDEC CORPORATION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| By: | /s/ Brian McLaughlin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Brian McLaughlin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chief Financial Officer and Executive Vice President of Finance and Administration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXHIBIT 3.1
AMENDMENT NO. 3 TO
BY-LAWS OF LANDEC CORPORATION
The first sentence of Section 3.2 of the By-Laws of Landec Corporation shall be amended and restated to read in its entirety as follows:
“The authorized number of directors shall be no fewer than six (6) and no more than twelve (12).”